trending Market Intelligence /marketintelligence/en/news-insights/trending/Jesx5sN-XrRRDs_5xyKVaw2 content esgSubNav
In This List

Neurotrope adds 2 directors

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Neurotrope adds 2 directors

Neurotrope Inc. appointed Ivan Gergel and Jonathan Schechter to its board.

Gergel is the managing partner and chief medical officer of New Rhein Healthcare Investors LLC, while Schechter is director of investment banking at Chardan Capital Markets.

Neurotrope is a biopharmaceutical company focused on developing a product platform for the treatment of Alzheimer's disease.